AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
← catalyst calendarNCT06137144 · readout in 988 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
161estimated
Sites
37
Countries
Australia, China, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-23 | actual | When the study began enrolling |
| Primary completion | 2029-05-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-03 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lymphoma
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
- Peripheral T-cell Lymphoma (PTCL)
- PTCL-NOS
- ALCL
- AITL
Interventions
- Drug: AZD3470
- Drug: Pembrolizumab — also filed as Keytruda
Primary outcomes
what the primary-completion date above is the date OFIncidence and severity of adverse events (AEs) and serious adverse events (SAEs)
measured From Screening continuously until 28 days after the last dose of study medication.
Incidence of DLTs (Dose Escalation Cohorts only)
measured From first dose of AZD3470 to end of Cycle 1 (each cycle is 21 days).
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed